Cytomx Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
CytomX Therapeutics reports positive early clinical data for Varseta-M and CX-801, alongside a significant net loss and collaboration terminations, while securing capital into Q2 2027.
NASDAQ
CytomX Therapeutics' 2024 10-K filing details the company's financial status, pipeline progress, and strategic shift towards prioritized programs and collaborations.
NASDAQ
CytomX Therapeutics, a clinical-stage biopharmaceutical company, released its 2023 financial results and provided an update on its pipeline of conditionally activated biologics.